A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs JNJ 56914845 (Primary) ; Simeprevir (Primary) ; TMC 647055 (Primary) ; Ribavirin; Ritonavir; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Feb 2017 Results published in the BMC Gastroenterology
- 16 Mar 2015 Results published in Medivir AB media release.
- 25 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.